Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
56.44
+0.44 (0.79%)
May 8, 2026, 4:00 PM EDT - Market closed
Xenon Pharmaceuticals Revenue
In the year 2025, Xenon Pharmaceuticals had annual revenue of $7.50M.
Revenue (ttm)
$7.50M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
370
Market Cap
5.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.50M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 9.43M | -9.00M | -48.83% |
| Dec 31, 2021 | 18.44M | -13.73M | -42.68% |
| Dec 31, 2020 | 32.17M | 25.34M | 371.02% |
| Dec 31, 2019 | 6.83M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 311.00K | -1.49M | -82.75% |
| Dec 31, 2016 | 1.80M | -13.77M | -88.43% |
| Dec 31, 2015 | 15.58M | -12.79M | -45.09% |
| Dec 31, 2014 | 28.37M | 1.01M | 3.71% |
| Dec 31, 2013 | 27.36M | 13.05M | 91.19% |
| Dec 31, 2012 | 14.31M | 7.39M | 106.82% |
| Dec 31, 2011 | 6.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Apellis Pharmaceuticals | 1.11B |
| Legend Biotech | 1.03B |
| Corcept Therapeutics | 769.10M |
| TG Therapeutics | 700.35M |
| Centessa Pharmaceuticals | 15.00M |
| CG Oncology | 5.07M |
| CRISPR Therapeutics AG | 4.10M |
XENE News
- 1 day ago - Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham - TheFly
- 2 days ago - Xenon Pharmaceuticals reports Q1 EPS ($1.17), consensus ($1.20) - TheFly
- 2 days ago - Xenon Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 2 days ago - Xenon Reports Q1 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 2 days ago - Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026 - GlobeNewsWire
- 8 days ago - Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Xenon to Report Q1 2026 Financial Results on May 7, 2026 - GlobeNewsWire
- 17 days ago - Xenon Pharmaceuticals Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference - Transcripts